Latest news with #Seigerman
Business Insider
31-05-2025
- Business
- Business Insider
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX)
BMO Capital analyst Evan Seigerman reiterated a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $557.00. The company's shares closed today at $441.97. Confident Investing Starts Here: According to TipRanks, Seigerman is a 4-star analyst with an average return of 3.7% and a 43.73% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Novo Nordisk, and Vertex Pharmaceuticals. In addition to BMO Capital, Vertex Pharmaceuticals also received a Buy from UBS's Eliana Merle in a report issued yesterday. However, today, Barclays maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
Business Insider
25-05-2025
- Business
- Business Insider
Analysts Have Conflicting Sentiments on These Healthcare Companies: Novo Nordisk (NVO), Beam Therapeutics (BEAM) and TScan Therapeutics (TCRX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novo Nordisk (NVO – Research Report), Beam Therapeutics (BEAM – Research Report) and TScan Therapeutics (TCRX – Research Report). Confident Investing Starts Here: Novo Nordisk (NVO) In a report issued on May 6, Evan Seigerman from BMO Capital maintained a Hold rating on Novo Nordisk, with a price target of $64.00. The company's shares closed last Friday at $67.35. According to Seigerman is a 4-star analyst with an average return of 3.2% and a 42.7% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Protagonist Therapeutics, and Arvinas Holding Company. The word on The Street in general, suggests a Hold analyst consensus rating for Novo Nordisk with a $92.44 average price target. BMO Capital analyst Kostas Biliouris maintained a Buy rating on Beam Therapeutics on May 7 and set a price target of $40.00. The company's shares closed last Friday at $16.83. According to Biliouris has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -17.1% and a 29.2% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Rocket Pharmaceuticals. Beam Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $44.13, implying a 164.3% upside from current levels. In a report issued on May 6, William Blair also maintained a Buy rating on the stock. TScan Therapeutics (TCRX) BTIG analyst Jeet Mukherjee maintained a Buy rating on TScan Therapeutics on May 21 and set a price target of $12.00. The company's shares closed last Friday at $1.38, close to its 52-week low of $1.34. According to Mukherjee has 0 stars on 0-5 stars ranking scale with an average return of -15.8% and a 31.6% success rate. Mukherjee covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Janux Therapeutics Inc, and Carisma Therapeutics. Currently, the analyst consensus on TScan Therapeutics is a Strong Buy with an average price target of $9.33, representing a 557.0% upside. In a report issued on May 6, TD Cowen also maintained a Buy rating on the stock.
Yahoo
20-05-2025
- Business
- Yahoo
BMO Capital Maintains Buy Rating on Pfizer (PFE) Stock
On May 20, BMO Capital analyst Evan Seigerman maintained a Buy rating on Pfizer Inc. (NYSE:PFE) and kept the price target the same at $30. The reiteration comes after the company recently announced entering into an exclusive licensing agreement with 3SBio, a leading Chinese biopharmaceutical company. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. The agreement entails the development, manufacturing, and commercialization of SSGJ-707, which is a bispecific antibody targeting PD-1 and VEGF. The drug is currently under clinical trials in China for treating non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. As per the preliminary data, the candidate has shown promising results and safety data. As per the agreement, Pfizer Inc. (NYSE:PFE) has secured exclusive global rights to manufacture and commercialize SSGJ-707 around the world, excluding China. Seigerman, in his note, regarded this agreement as a significant move to expand the company's oncology portfolio and leverage its collaborations to enhance its strategic edge. However, he also acknowledged the high cost of this agreement. Pfizer Inc. (NYSE:PFE) will pay 3SBio $1.25 billion upfront, with total development milestone payments reaching up to $4.8 billion. Additionally, 3SBio will receive tiered double-digit royalties on sales if the drug is approved. Moreover, Seigerman highlighted that Pfizer Inc. (NYSE:PFE) is currently undervalued in comparison to its United States peers and has gained a strategic advantage through transformative acquisitions. The analyst highlighted the company's operational efficiency, conservative revenue guidance for 2025, and potential clinical developments in areas such as oncology and obesity being the major reasons for optimism. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
07-05-2025
- Health
- CNBC
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Despite last week's investor jitters, Eli Lilly is far from losing its strong grip on the booming weight loss market. Here's a recap of what sparked the panic on Thursday if you missed it: CVS Health 's pharmacy benefit manager Caremark said it will prioritize Novo Nordisk 's Wegovy on its standard formularies on July 1, making that weekly injection the preferred GLP-1 drug for obesity. As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from those formularies, which represent tens of millions of patients. Caremark negotiated an undisclosed lower net price for Wegovy over Zepbound on its standard formularies, offering savings on Novo Nordisk's drug to clients that opt into those plans. But employers and unions will ultimately determine how much of those savings on Wegovy get shared with members, CVS said. Wegovy's list price before insurance is $1,349 for a month's supply, while Zepbound's is $1,086. That decision by one of the nation's largest PBMs triggered fears of a price war in the weight loss drug market and concerns that Zepbound's sales momentum could stall. Shares of Eli Lilly plunged 11% on Thursday. But several Wall Street analysts said the selloff was overblown. "In our view, the Novo/CVS deal does not represent the beginning of an obesity pricing war between Lilly & Novo," BMO Capital Markets analyst Evan Seigerman said in a note on Thursday. He added that in discussions with the companies, both Lilly and Novo emphasized they want to expand patient access – not undercut each other on price. That may be reassuring to investors worried that a price war could hurt profit margins. But the high list price of those weight loss drugs may remain a major barrier for many patients, particularly those whose health plans don't cover the medications. Eli Lilly told the firm it is not interested in exclusive "one-of-one" deals with PBMs, while Novo Nordisk said CVS approached the drugmaker about the Wegovy agreement, according to Seigerman. On an earnings call on Thursday, Eli Lilly CEO David Ricks said the company has been trying to move away from setting high list prices and paying bigger rebates to PBMs for preferential coverage. Instead, Eli Lilly is trying to set list prices closer to what it expects the plans to pay for its drugs. "We have been very vocal about trying to move away from that," Ricks said, referring to deep PBM rebates. He added that Zepbound is still growing market share. Seigerman agreed, saying that Eli Lilly is "continuing to perform where it matters." Zepbound and the company's diabetes drug Mounjaro now make up over half of U.S. GLP-1 prescriptions, outpacing the combined 46% share of Novo Nordisk's Wegovy and its diabetes treatment Ozempic, according to Seigerman. That "market-share traction clearly demonstrates that physicians and patients prefer Zepbound" over Wegovy, Bernstein analyst Courtney Breen wrote in a separate note on Thursday. It's unclear how much the CVS formulary change will appeal to employers, especially given that Zepbound is known to be more effective at promoting weight loss than Wegovy. Some patients on the standard formularies may also try to stay on their current Zepbound prescriptions by requesting exemptions, JPMorgan analyst Chris Schott said in a Thursday note. Eli Lilly's Ricks also said CVS' move mainly affects smaller employers, who are more likely to stick with Caremark's standard formularies. Larger companies covering more patients often use customized formularies, meaning they can still decide to include Zepbound. Regardless, the CVS-Wegovy deal overshadowed an overall strong quarter for Eli Lilly. The company's first-quarter revenue and earnings topped estimates on skyrocketing demand for Zepbound and Mounjaro, both of which raked in billions of dollars in sales for the period. We'll continue to track Eli Lilly's performance in the weight loss drug market, so stay tuned! Feel free to send any tips, suggestions, story ideas and data to Annika at Health-care marketplace Zocdoc has launched an artificial intelligence phone assistant that can help patients schedule appointments using conversational language. ZocDoc, founded in 2007, helps connect patients to in-network doctors and book appointments for both in person and virtual care. The company's new AI assistant, called Zo, can handle "unlimited" inbound calls at any hour of the day, eliminating hold times, ZocDoc said in a release. The company said Zo can save staffers time and improve patients' experiences, which can ultimately encourage them to seek out the care they need. The assistant also serves as a major step toward what the company called its goal of aiding scheduling "everywhere patients are seeking care." "What's most exciting about Zo is that it is powered by nearly two decades of Zocdoc's expertise in facilitating patient-provider interactions, understanding complex healthcare scheduling logic, and integrating with a broad base of [electronic health records]," Zocdoc CEO Oliver Kharraz said in a statement. Patients can ask Zo questions like, "Do you take my insurance?," or "Do you have any offices near the West Village?," according to a pre-recorded demo. Health-care organizations can implement Zo without any upfront fees, long-term costs or commitments, and they don't have to be Zocdoc Marketplace customers, the company said. Providers can try out the assistant for $2 per booked appointment, but organizations that want to roll it out on a larger scale can access discounted pricing. Zocdoc said early adopters of Zo have been able to resolve up to 70% of all scheduling calls without staff intervention. The average call lasts around two minutes and 30 seconds. While appointment management is Zo's first use case, Zocdoc said it's exploring other applications for the assistant, including prescription refills, messaging and outbound calls like appointment reminders or last-minute openings. Read the full announcement here. Feel free to send any tips, suggestions, story ideas and data to Ashley at
Yahoo
28-04-2025
- Business
- Yahoo
Why AbbVie Stock Trounced the Market Today
The positive, post-earnings momentum lifting AbbVie's (NYSE: ABBV) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session. The key reason was a pair of bullish analyst notes on its business. That rise meant the stock easily beat the S&P 500 index, which could only manage a less than 0.1% gain. Of the two notes, arguably the more impactful was the one BMO Capital's Evan David Seigerman published before market open. The analyst continues to be positive on AbbVie, as he maintained his outperform (buy, in other words) recommendation on the stock and $215 per-share price target. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Not surprisingly, according to reports, Seigerman focused on AbbVie's first-quarter earnings release that was published on Friday. The analyst said that management was continuing to execute well, particularly in relation to important high revenue-generating products Skyrizi and Rinvoq. He pointed out that the unexpectedly high sales of the pair of drugs offset the anticipated declines of Humira. Seigerman was also cheered by what he considered to be a justifiable raise in per-share earnings guidance by the company. Additionally, the company could gain from favorable foreign exchange movements, in his view. AbbVie also got a boost from global bank HSBC, which published a somewhat dispiriting update that morning on several prominent healthcare titles. In its report, the company downgraded several stocks under its coverage. Among other moves, it changed its recommendation on Zepbound maker Eli Lilly to reduce from buy. On the flip side, HSBC flagged several sector names as being buys; among those it considers to be a good value for the money these days is AbbVie. Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!* Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 HSBC Holdings is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends AbbVie. The Motley Fool recommends HSBC Holdings. The Motley Fool has a disclosure policy. Why AbbVie Stock Trounced the Market Today was originally published by The Motley Fool
